Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 8/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | ICMT | O60725 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3006668 | 0.89 | L3MBTL1 (0.72) | L3MBTL1HTR6AKR1C3EPHX1AKR1C2 | |
| SCHEMBL3220344 | 0.86 | L3MBTL1 (0.56) | L3MBTL1HTR6AKR1C3EPHX1AKR1C2 | |
| SCHEMBL29444455 | 0.86 | L3MBTL1 (0.56) | L3MBTL1HTR6AKR1C3EPHX1AKR1C2 | |
| SCHEMBL2018732 | 0.83 | L3MBTL1 (0.78) | L3MBTL1HTR6AKR1C3EPHX1PDE10A | |
| SCHEMBL29651147 | 0.83 | L3MBTL1 (0.78) | L3MBTL1HTR6AKR1C3EPHX1PDE10A | |
| SCHEMBL17871942 | 0.82 | L3MBTL1 (0.52) | L3MBTL1HTR6AKR1C3AKR1C2F2 | |
| SCHEMBL26683954 | 0.79 | L3MBTL1 (0.56) | L3MBTL1HTR6AKR1C3EPHX1PDE10A | |
| SCHEMBL16880872 | 0.79 | L3MBTL1 (0.58) | L3MBTL1HTR6AKR1C3EPHX1AKR1C2 | |
| SCHEMBL28942631 | 0.78 | HTR6 (0.46) | L3MBTL1HTR6EPHX1NR1H2 | |
| SCHEMBL27807453 | 0.77 | HTR6 (0.46) | L3MBTL1HTR6AKR1C3EPHX1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237396-B1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2019-07-03 | — | — | EP | disclosed |
| EP-3237396-B1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2019-07-03 | — | — | EP | disclosed |
| US-9902725-B2 | Heterocyclic derivatives as RORgamma modulators | GENFIT (FR) | 2018-02-27 | — | — | US | disclosed |
| US-20170349582-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2017-12-07 | — | — | US | disclosed |
| US-20170349582-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2017-12-07 | — | — | US | disclosed |
| EP-3237396-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | Genfit (FR) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016102633-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349582-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | RORC, RORB, RORA | L3MBTL1 4499/4885HTR6 4445/4885AKR1C3 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.